RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC Read more →
MapLight shares sink on mixed phase 2 schizophrenia readout Read more →
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears Read more →
Perm Director
